Resorbable Magnesium Scaffolds Registry
RMS (Resorbable Magnesium Scaffolds) Registry
Biotronik AG
1,106 participants
Nov 18, 2020
OBSERVATIONAL
Conditions
Summary
The registry follows the ESC/EACTS guideline and further investigates the clinical performance and short-term safety of RMS (Resorbable Magnesium Scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (IFU).
Eligibility
Inclusion Criteria1
- According to the IFU
Exclusion Criteria1
- According to the IFU
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Freesolve is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04679740